Section
The FDA has approved depemokimab (Exdensur), the first long-acting biologic for severe eosinophilic asthma. Requiring only two doses per year, it significantly reduces exacerbations and hospitalizations, offering a transformative shift in t
A Phase 1/2 clinical trial demonstrates that PM359, an autologous prime-edited CD34+ cell therapy, successfully corrects the delGT mutation in NCF1, restoring essential microbicidal function in patients with p47-CGD without the off-target r
The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark
A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–mo
Three complementary studies—EVEREST (head‑to‑head RCT), the US ADVANTAGE real‑world study, and a target‑trial emulation—consistently show greater reductions in nasal polyp burden, smell loss, asthma exacerbations, and systemic steroid use w
Two large US retrospective cohort studies show seborrheic dermatitis is strongly associated with a range of epithelial barrier diseases (skin, respiratory, gastrointestinal, ocular), with evidence of bidirectional risk. Findings support the
A first large GWAS in 4,602 idiopathic achalasia patients implicates class II HLA variation, PTPN22, TNFSF loci and a memory CD8+ T-cell subtype in disease pathogenesis, supporting an immune-mediated aetiology and offering routes for mechan
Analysis of MASK‑air app data from 2015–2022 found lower self‑reported adherence to ICS+formoterol versus other ICS+LABA combinations, but paradoxically lower short‑acting β2‑agonist (SABA) use and similar symptom control in ICS+formoterol
New research reveals that galactose from dietary sources like milk reprograms liver metabolism, boosting immune T cell activity to combat tumors by preventing their exhaustion.
A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.
This study reveals multiple distinct molecular mechanisms, including epithelial and macrophage pathways, that contribute to residual asthma exacerbations in children treated with mepolizumab, highlighting the complexity of airway inflammati
This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.
Marengo Therapeutics reports promising Phase 2 results for invikafusp alfa, showing significant tumor shrinkage and disease control in advanced solid tumors with high mutation burden or MSI-H/dMMR.
This study explores how biological sex influences CRS diagnosis and inflammatory biomarkers, revealing sex-specific patterns that could inform personalized treatment.
This article explores the clinical features, underlying mechanisms, and potential therapeutic targets for chronic rejection in VCA, emphasizing the importance of tailored interventions to improve long-term graft survival.
The Basophil Activation Test offers the highest accuracy in predicting allergic reactions to baked and fresh cow’s milk during oral food challenges, reducing the need for riskier diagnostic tests in children with milk allergy.
The APPEAR-C3G phase 3 trial demonstrates that oral iptacopan significantly reduces proteinuria and is well tolerated in adults with C3 glomerulopathy, an ultra-rare glomerulonephritis linked to alternative complement pathway overactivation
Longitudinal data from the French NutriNet-Santé cohort reveal that persistent and increased use of green cleaning products is associated with a modest but significant rise in asthma symptoms, underscoring the need for cautious use and pati
This systematic review highlights patient and caregiver priorities in chronic urticaria treatment, emphasizing rapid symptom relief, long-term effectiveness, and safety.
The 2025 Nobel Prize in Physiology or Medicine honors groundbreaking work on regulatory T cells, revealing how the immune system avoids self-attack while combating threats, paving the way for novel therapies in autoimmune and transplant med
